Q2 2021 Results - Reimagining Medicine
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
References
References
Consistent long-term performance
1
2
Cosentyx®, EntrestoⓇ, ZolgensmaⓇ, KisqaliⓇ, Mayzent®, Tafinlar+MekinistⓇ, JakaviⓇ, BeovuⓇ, XiidraⓇ, AimovigⓇ, XolairⓇ.
LutatheraⓇ, KymriahⓇ, Piqray®, AdakveoⓇ, KesimptaⓇ, Leqvio®, TabrectaⓇ, Asciminib.
3 Brands with 2024 consensus sales lower than 2019 actual sales (Glivec®, Tasigna®, Afinitor®, VotrientⓇ, Promacta®, Exjade®, SandostatinⓇ®, Galvus®, GilenyaⓇ, LucentisⓇ).
EntrestoⓇ
1
2
3
IQVIA National Prescription Audit
2021 Update to the 2017 ACC Expert Consensus Decision Pathway (ECDP) for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction
https://www.jacc.org/doi/10.1016/j.jacc.2020.11.022
Update to ESC heart Failure guidelines as presented at ESC-HF (28 Jun - 1 Jul 20201). Complete and final guideline to be released in August 2021
LeqvioⓇ
1
2
3
4
5
6
7
Data on file; American Heart Association. Center for Health Metrics and Evaluation. Accessed at: https://healthmetrics.heart.org/prevalence-and-number-of-us-adults-eligible-for-and-currently-using-statin-therapy-nhanes-2011-2014/;
Wong ND. Journal of Clinical Lipidology. 2016;10(5):1109-1118; American Heart Association/American Stroke Association. Cardiovascular Disease: A Costly Burden
<70mg/dL
Non-statin lipid lowering therapies include ezetimibe and PCSK9i mAbs.
LAAD; IQVIA US Market Access Strategy Consulting.
Percentages in table refer to share of eligible US population
Medicaid, federal.
In patients with elevated LDL-C despite treatment with maximally tolerated statin therapy. V-INITIATE NCT04929249; V-INCEPTION NCT04873934
Asciminib
Difference: 12.2% (95% confidence interval: 2.19, 22.30, two-sided p-value: 0.029) per the Cochran-Mantel-Haenszel test which is stratified by baseline major cytogenetic response status, cut-off date 25-May-2020
Specifically Targeting BCR-ABL Myristoyl Pocket.
1
2
3
4
ELN recommendations 2019
Garcia-Gutierrez V and Hernandez-Boluda JC, Front. Oncol. 2019; 9:603
177Lu-PSMA-617
1
2
3
Epidemiology of Prostate Cancer. Rawla P., World J Oncol. 2019;10(2):63-89
Characterizing the castration-resistant prostate cancer population: a systematic review. M. Kirby et all., Int J Clin Pract. 2011;65(11):1180-92
In men with progressive mCRPC after docetaxel and abiraterone and/or enzalutamide, Smith et al., Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1, J Clin Oncol
34:3005-3013
4
Sartor et al, NEJM, 2021, DOI: 10.1056/NEJMoa210732
5
Novartis primary market research ATU, May 2020 & June 2021
55 Investor Relations | Q2 2021 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation